Cargando…

Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses

INTRODUCTION: Coronavirus disease 2019 resulted in a 30% mortality rate in patients with thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine registration trials, it is still unknown whether they would deve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gounant, Valérie, Ferré, Valentine Marie, Soussi, Ghassen, Charpentier, Charlotte, Flament, Héloïse, Fidouh, Nadhira, Collin, Gilles, Namour, Céline, Assoun, Sandra, Bizot, Alexandra, Brouk, Zohra, Vicaut, Eric, Teixeira, Luis, Descamps, Diane, Zalcman, Gérard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Association for the Study of Lung Cancer. Published by Elsevier Inc. 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8593625/ https://www.ncbi.nlm.nih.gov/pubmed/34798306 http://dx.doi.org/10.1016/j.jtho.2021.10.015

Ejemplares similares

Humoral Response to SARS-CoV-2 mRNA Vaccine in Heart Transplant Recipients up to 4 Months After the Third Vaccine Injection
por: Ferré, V.M., et al.
Publicado: (2022)

Decreasing humoral response among healthcare workers up to 4 months after two doses of BNT162b2 vaccine
por: Ferré, Valentine Marie, et al.
Publicado: (2022)

Patients avec cancers thoraciques et COVID-19 : au cœur de la tempête: Patients with chest cancer and COVID-19: at the heart of the storm
por: Gounant, V., et al.
Publicado: (2021)

Vaccine Ab neutralization against Omicron and SARS-CoV-2 variants using neutralization and specific ELISA assays
por: Ferré, Valentine Marie, et al.
Publicado: (2022)

Evaluation of three extraction-free SARS-CoV-2 RT-PCR assays: A feasible alternative approach with low technical requirements
por: Visseaux, Benoit, et al.
Publicado: (2021)

SARS-CoV-2 IGM and IGG rapid serologic test for the diagnosis of COVID-19 in the emergency department
por: Cancella de Abreu, Marta, et al.
Publicado: (2020)

Impact of Low-Dose Methotrexate–Adalimumab Combination Therapy on the Antibody Response Induced by the mRNA-1273 SARS-CoV-2 Vaccine: Case of an Elderly Patient with Rheumatoid Arthritis
por: Michiels, Yves, et al.
Publicado: (2021)

Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position article
por: Barrière, Jérôme, et al.
Publicado: (2022)

Alpha (B.1.1.7) and Delta (B.1.617.2 – AY.40) SARS-CoV-2 variants present strong neutralization decay at M4 post-vaccination and a faster replication rates than D614G (B.1) lineage
por: Lebourgeois, Samuel, et al.
Publicado: (2022)

Grade 3–4 Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer (NSCLC) Patients Are Correlated with Better Outcome: A Real-Life Observational Study
por: Guezour, Nadia, et al.
Publicado: (2022)

(61) Prevalence and Determinants of Cellular Immunity Against Sars-Cov-2 in Heart Transplant Recipients: A Cross-Sectional Study
por: Flament, H., et al.
Publicado: (2023)

Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient
por: Michiels, Yves, et al.
Publicado: (2021)

Evaluation of the RealStar® SARS-CoV-2 RT-PCR kit RUO performances and limit of detection
por: Visseaux, Benoit, et al.
Publicado: (2020)

Earlier In Vitro Viral Production With SARS-CoV-2 Alpha Than With Beta, Gamma, B, or A.27 Variants
por: Lebourgeois, Samuel, et al.
Publicado: (2021)

Epidermal growth factor receptor-mutant non-small cell lung Cancer and Choroidal metastases: long-term outcome and response to epidermal growth factor receptor tyrosine kinase inhibitors
por: Bouchez, Clémentine, et al.
Publicado: (2020)

Contribution of rapid lateral flow assays from capillary blood specimens to the diagnosis of COVID-19 in symptomatic healthcare workers: a pilot study in a university hospital, Paris, France
por: Charpentier, Charlotte, et al.
Publicado: (2021)

Transthoracic lung biopsy for pulmonary nodules ≤20 mm in routine clinical care
por: Lissavalid, Emilie, et al.
Publicado: (2022)

Performance evaluation of two SARS-CoV-2 IgG/IgM rapid tests (Covid-Presto and NG-Test) and one IgG automated immunoassay (Abbott)
por: Charpentier, Charlotte, et al.
Publicado: (2020)

Usefulness of multiplex PCR methods and respiratory viruses’ distribution in children below 15 years old according to age, seasons and clinical units in France: A 3 years retrospective study
por: Visseaux, Benoit, et al.
Publicado: (2017)

The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients
por: Teyssou, Elisa, et al.
Publicado: (2021)

Immunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
por: Gounant, Valérie, et al.
Publicado: (2021)

Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease
por: Quan, Joshua, et al.
Publicado: (2023)

Vaccine dosing controversy
por: Wilson, Clare
Publicado: (2021)

Serological response to a single dose of a SARS-CoV-2 mRNA vaccine
por: Ramos, Angélica, et al.
Publicado: (2021)

Vaccine coverage and compliance in Mexico with the two-dose and three-dose rotavirus vaccines
por: Luna-Casas, Gerardo, et al.
Publicado: (2018)

Does Very Poor Performance Status Systematically Preclude Single Agent Anti-PD-1 Immunotherapy? A Multicenter Study of 35 Consecutive Patients
por: Gounant, Valérie, et al.
Publicado: (2021)

Molecular confirmation of HIV-1 and HIV-2 coinfections among initially serologically dually-reactive samples from patients living in West Africa
por: Tchounga, Boris K., et al.
Publicado: (2023)

286. Hepatitis B Vaccine Compliance: Comparing 2-Dose and 3-Dose Vaccines
por: Bruxvoort, Katia, et al.
Publicado: (2019)

Serological response to one intradermal or intramuscular hepatitis B virus vaccine booster dose in human immunodeficiency virus-infected nonresponders to standard vaccination
por: Ramezani, Amitis, et al.
Publicado: (2014)

The 501Y.V2 SARS-CoV-2 variant has an intermediate viral load between the 501Y.V1 and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients
por: Teyssou, Elisa, et al.
Publicado: (2021)

Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
por: Branagan, Andrew R., et al.
Publicado: (2021)

Serological Response to Three, Four and Five Doses of SARS-CoV-2 Vaccine in Kidney Transplant Recipients
por: Osmanodja, Bilgin, et al.
Publicado: (2022)

Serological response to a third dose of SARS-CoV-2 vaccine according to previous infection history
por: Ota, Kenji, et al.
Publicado: (2023)

Serological responses to the first four doses of SARS-CoV-2 vaccine in patients with inflammatory bowel disease
por: Quan, Joshua, et al.
Publicado: (2022)

Serological response following COVID-19 vaccines in patients living with HIV: a dose–response meta-analysis
por: Zhou, Qian, et al.
Publicado: (2023)

Future of Antiretroviral Drugs and Evolution of HIV-1 Drug Resistance
por: Charpentier, Charlotte, et al.
Publicado: (2023)

HIV-2 diversity displays two clades within group A with distinct geographical distribution and evolution
por: Visseaux, Benoit, et al.
Publicado: (2021)

High torque tenovirus (TTV) load before first vaccine dose is associated with poor serological response to COVID-19 vaccination in lung transplant recipients
por: Hoek, Rogier AS, et al.
Publicado: (2022)

NACI greenlights second doses, dose splitting of monkeypox vaccine
por: Vogel, Lauren
Publicado: (2022)

Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines
por: Narasimhan, Madhusudhanan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3el180a1oiotipmoe4muc5rhue